Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John McDonald

Sports Medicine Austin, TX Medical Doctor

NPI 1780896241 CMS profile 35273

4700 Seton Center Pkwy, Suite 200, Austin, TX 78759

Open in the dashboard

General payments

$498,699

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John McDonald of Austin, TX is reported in the CMS Open Payments database as having received $498,699 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $109,920 10
2024 General $123,733 29
2023 General $96,306 12
2022 General $120,582 32
2021 General $35,584 12
2020 General $5,188 5
2019 General $7,386 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John McDonald
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to John McDonald were reported at $109,920. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year John McDonald Sports Medicine median Middle half National median
2019 $7,386 $1,176 $199–$4,249 $163
2020 $5,188 $708 $96–$2,890 $114
2021 $35,584 $1,213 $152–$3,994 $132
2022 $120,582 $1,230 $159–$3,998 $149
2023 $96,306 $584 $146–$2,836 $160
2024 $123,733 $628 $163–$3,168 $164
2025 $109,920 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $494,608 85 payments
  2. Medinc of Texas $2,382 2 payments
  3. Stryker Corporation $1,010 9 payments
  4. Medacta USA, Inc. $653 5 payments
  5. DePuy Synthes Sales Inc. $22 1 payment
  6. Core Surgical Group $14 1 payment
  7. Actelion Pharmaceuticals US, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $417,642 19 payments
  2. Consulting Fee $46,369 23 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,988 10 payments
  4. Travel and Lodging $3,231 15 payments
  5. Education $2,382 2 payments
  6. Food and Beverage $2,089 35 payments
Products named General payments · program years 2019–2025
  1. BICEPTOR $208,387 11 payments
  2. Coblation $109,046 8 payments
  3. SPATIAL FRAME $13,131 3 payments
  4. CAP-FIX $10,500 2 payments
  5. Q-FIX $10,500 2 payments
  6. AMBIENT HIPVAC $7,375 3 payments
  7. Elite Hip Instruments $7,375 3 payments
  8. Bone Anchors with Arthroscopic Delivery System $7,248 3 payments
  9. HEALICOIL $7,219 2 payments
  10. FAST-FIX $6,423 6 payments
  11. Other $58,413 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

94

Median for Orthopedic Surgery: 203

Drug cost

$439

Median for Orthopedic Surgery: $1,433

Branded share of claims

19.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naproxen Generic 23 $180
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $144
Meloxicam Generic 36 $72
Ondansetron Hcl Generic 17 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$45,505

Of which drugs: $3,092

Medicare patients

139

Average age 70

Services billed

1,452

78 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 41%
Ischemic heart disease 29%
Depression 17%
Diabetes 14%
Osteoporosis 13%
Atrial fibrillation 12%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 66 521 $380

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record